Scholarlink

<p>Late-onset sinusoidal obstruction syndrome (SOS) after allogeneic hematopoietic cell transplantation remains difficult to diagnose and treat. We retrospectively analyzed 14 umbilical cord blood transplant recipients who developed late-onset SOS and received defibrotide at Toranomon Hospital between 2019 and 2021. All patients presented with very severe SOS accompanied by multiorgan failure. The cumulative incidence of complete remission was 35.7% at one year after initiation of defibrotide therapy. Overall survival was 57.1% at day 100 and 35.7% at two years after SOS diagnosis. Patients with anicteric SOS tended to have better survival than those with icteric disease. Defibrotide was generally well tolerated, with only two grade ≥ 3 bleeding events. Despite the small sample size and retrospective design, these findings suggest that Defibrotide may provide clinical benefit in patients with late-onset SOS following umbilical cord blood transplantation.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Defibrotide for late-onset sinusoidal obstruction syndrome following umbilical cord blood transplantation: a single-center retrospective study

  • 期刊论文

  • 发表日期：

    2026年4月13日

查看全文
  • Yuki Shimizu,
  • Shinsuke Takagi,
  • Maki Higuchi,
  • Mika Kuno,
  • Otoya Watanabe,
  • Kyosuke Yamaguchi,
  • Kosei Kageyama,
  • Yuki Taya,
  • Daisuke Kaji,
  • Aya Nishida,
  • Hisashi Yamamoto,
  • Hideki Araoka,
  • Yuki Asano-Mori,
  • Go Yamamoto,
  • Atsushi Wake,
  • Shuichi Taniguchi,
  • Naoyuki Uchida

摘要

Late-onset sinusoidal obstruction syndrome (SOS) after allogeneic hematopoietic cell transplantation remains difficult to diagnose and treat. We retrospectively analyzed 14 umbilical cord blood transplant recipients who developed late-onset SOS and received defibrotide at Toranomon Hospital between 2019 and 2021. All patients presented with very severe SOS accompanied by multiorgan failure. The cumulative incidence of complete remission was 35.7% at one year after initiation of defibrotide therapy. Overall survival was 57.1% at day 100 and 35.7% at two years after SOS diagnosis. Patients with anicteric SOS tended to have better survival than those with icteric disease. Defibrotide was generally well tolerated, with only two grade ≥ 3 bleeding events. Despite the small sample size and retrospective design, these findings suggest that Defibrotide may provide clinical benefit in patients with late-onset SOS following umbilical cord blood transplantation.